Filippa Pettersson

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].

Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].

Journal: The Journal of investigative dermatology
Published: March 13, 2026

Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.

Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.

Journal: Cancer
Published: December 04, 2024

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.

Journal: Molecular cancer therapeutics
Published: March 15, 2021

Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.

Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 19, 2021

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Journal: Current oncology (Toronto, Ont.)
Published: January 05, 2019

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.

Journal: eLife
Published: June 22, 2017

Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis.

Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis.

Journal: Cell death and differentiation
Published: February 27, 2017

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Journal: Leukemia & lymphoma
Published: May 18, 2016

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.

Journal: Cancer research
Published: January 23, 2015

Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.

Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.

Journal: Expert opinion on therapeutic targets
Published: July 10, 2014

The role of eIF4E in response and acquired resistance to vemurafenib in melanoma.

The role of eIF4E in response and acquired resistance to vemurafenib in melanoma.

Journal: The Journal of investigative dermatology
Published: January 04, 2014

Pharmacological targeting of eIF4E in primary CLL lymphocytes.

Pharmacological targeting of eIF4E in primary CLL lymphocytes.

Journal: Blood cancer journal
Published: September 17, 2013
Showing 1-12 of 14

Last Updated: 09/26/2026